Fluticasone propionate/formoterol for COPD management: a randomized controlled trial

Area of Science:

• Pulmonology
• Pharmacology
• Clinical Trials

Background:

• Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disease characterized by persistent airflow limitation.
• Exacerbations significantly impact patient outcomes and healthcare costs.
• Inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combinations are a cornerstone of COPD management.

Purpose of the Study:

• To evaluate the efficacy and safety of fluticasone propionate/formoterol (FP/FORM) compared to formoterol (FORM) alone in patients with moderate to severe COPD.
• To assess the impact of two different FP/FORM dosages (500/20 µg and 250/10 µg) on exacerbation rates and other clinical outcomes.

Main Methods:

• A 52-week randomized, double-blind, controlled trial involving 1,765 COPD patients with a history of exacerbations.
• Patients received FP/FORM 500/20 µg, FP/FORM 250/10 µg, or formoterol 12 µg twice daily.
• Primary endpoint was the annualized rate of moderate/severe COPD exacerbations; secondary endpoints included lung function, symptom scores, and safety events.

Main Results:

• Neither FP/FORM dose significantly reduced the rate of moderate/severe exacerbations compared to formoterol alone.
• The FP/FORM 500/20 µg dose showed trends towards lower exacerbation rates in specific subgroups and improvements in lung function (FEV1, FVC), EXACT exacerbation rates, SGRQ-C scores, and respiratory symptom scores.
• Pneumonia incidence was higher in the FP/FORM groups (2.4% and 3.2%) compared to the formoterol group (1.5%), though absolute differences were small.

Conclusions:

• Fluticasone propionate/formoterol did not demonstrate a statistically significant reduction in COPD exacerbation rates compared to formoterol monotherapy.
• The higher dose of FP/FORM (500/20 µg) provided numerical benefits in secondary efficacy endpoints, suggesting potential clinical relevance for certain patient subgroups.
• While adverse events were generally similar, the increased incidence of pneumonia in FP/FORM-treated patients warrants consideration.